LUM GmbH Partners with Alpharmaca Inc. to Expand Chinese Sales Network Amid Growing Demand
LUM GmbH has recently entered into a strategic partnership with Alpharmaca Inc., a Shanghai-based company, to meet the increasing demand from the pharmaceutical and semiconductor sectors. This collaboration aims to enhance local expertise in particle characterization and materials testing.
Founded in 2010, Alpharmaca serves as a resource platform for China's industrial 4.0 transformation, introducing advanced technologies and products from around the world. The company focuses on nanotechnology within the pharmaceutical industry while covering various sectors, including biotechnology, chemicals, and semiconductors.
Susanne Lerche-Merchant, CEO of LUM GmbH, expressed enthusiasm for the partnership, stating, “This collaboration strengthens our market presence in crucial future industries, benefiting both current and prospective customers.” The LUMiSpoc single particle counter will provide solutions for particle counting and size distribution, essential in the pharmaceutical sector, including applications in COVID-19 vaccine development.
In addition to pharmaceuticals, the semiconductor industry relies heavily on grinding and polishing pastes, where precise particle characterization and stability assessment are critical. LUM's technologies will soon be utilized in Alpharmaca's application laboratory, offering customers varied insights into their samples.
This partnership marks a significant step in LUM's ongoing international strategy, aiming to address the needs of dynamic industries.
2026-10-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
The FDA Officially Blesses AI for Liver Drug Development
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
FDA Dye Tracker Raises Reformulation Pressure Across Food Brands
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
U.S. Congress Passes Bill Authorizing Tariffs of Up to 100% on Major Buyers of Russian Energy
Recommend Reading
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
FDA Dye Pledges Push Natural Colors Into the Mainstream
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
This week, China's acetone market continues to weaken
-
Ammonium Sulfate Market Prices Slightly Increase (11.17-11.21) in China
-
This Week, China's Phenol Market Rises and Then Falls
-
Understanding PCl5: Compound Name and Uses
-
MTBE Market Trend Weakly Consolidates